About: Characteristics of pulmonary complications in non-Hodgkin’s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characteristics of pulmonary complications in non-Hodgkin’s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Characteristics of pulmonary complications in non-Hodgkin’s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival
Creator	Van De Louw, Andry Bender, Regis Keefer, Kimberly Liao, Jason Sivik, Jeffrey
Source	PMC
abstract	Patients with non-Hodgkin’s lymphoma (NHL) receiving rituximab-containing chemotherapy are at risk of developing respiratory complications, but comprehensive information on these complications and their impact on survival is lacking. We performed a retrospective cohort analysis on 123 NHL patients who received rituximab-containing chemotherapy between 2009 and 2016 in order to describe the incidence, etiologies and effect on survival of respiratory complications defined by new or worsening respiratory symptoms requiring diagnostic work-up or hospitalization. Thirty patients (24%) developed respiratory complications during a follow-up time of 825 (555–1338) days after chemotherapy. They had a higher prevalence of congestive heart failure and lung or pleural involvement at diagnosis as compared to patients who did not develop complications. Overall, 58 episodes of pulmonary complications were observed after median (interquartile) times from the first and last rituximab doses of 205 (75–580) days and 27 (14–163) days respectively. Infectious etiologies accounted for 75% of the respiratory complications, followed by heart failure exacerbation, lymphomatous involvement, and ARDS. Two Pneumocystis jirovecii pneumonias were observed, and no complication was ascribed to rituximab toxicity. Respiratory complications required ICU admission in 19 cases (33%) and invasive mechanical ventilation in 14 cases (24%). Using a time-dependent Cox regression analysis, we observed that the occurrence of respiratory complications was associated with a 170% increase in death hazard (hazard ratio 2.65, 95% CI 1.60–4.40, p = 0.001). In conclusion, respiratory complications in NHL patients receiving chemotherapy are relatively frequent, severe, and mostly infectious and are associated with increased mortality.
has issue date	2018-07-21(xsd:dateTime)
bibo:doi	10.1007/s00277-018-3448-9
bibo:pmid	30030570
has license	no-cc
sha1sum (hex)	7750d9063d8114ab66c75e7d5f40f21eabd43546
schema:url	https://doi.org/10.1007/s00277-018-3448-9
resource representing a document's title	Characteristics of pulmonary complications in non-Hodgkin’s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival
has PubMed Central identifier	PMC7102168
has PubMed identifier	30030570
schema:publication	Ann Hematol
resource representing a document's body	covid:7750d9063d8114ab66c75e7d5f40f21eabd43546#body_text
is schema:about of	named entity 'rituximab' named entity 'respiratory' named entity 'chemotherapy' named entity 'patients' named entity 'prevalence' named entity 'complications' named entity 'Characteristics' named entity 'OVERALL' named entity 'PERFORMED' named entity 'DOSES' named entity 'TO DESCRIBE' named entity 'FREQUENT' named entity 'FOLLOWED BY' named entity 'RECEIVING' named entity '170' named entity 'ASSOCIATED WITH' named entity '580' named entity 'ORDER' covid:arg/7750d9063d8114ab66c75e7d5f40f21eabd43546 named entity 'risk' named entity 'comprehensive' named entity 'chemotherapy' named entity 'mechanical ventilation' named entity 'impact' named entity 'toxicity' named entity 'invasive' named entity 'order' named entity 'higher' named entity 'They' named entity 'hazard ratio' named entity 'lung' named entity 'etiologies' named entity 'regression analysis' named entity 'median' named entity 'days' named entity 'chemotherapy' named entity 'non-Hodgkin's lymphoma' named entity 'retrospective cohort' named entity 'invasive mechanical ventilation' named entity 'respiratory symptoms' named entity 'chemotherapy' named entity 'ICU' named entity 'chemotherapy' named entity 'CT scans' named entity 'comorbidities' named entity 'Pennsylvania State University' named entity 'respiratory complications' named entity 'antigen' named entity 'interstitial lung disease' named entity 'chemotherapy' named entity 'acute respiratory failure' named entity 'NHL' named entity 'chemotherapy' named entity 'granulocyte colony-stimulating factor' named entity 'radiation therapy' named entity 'Herpes simplex virus' named entity 'mechanical ventilation' named entity 'CHF' named entity 'adverse events' named entity 'pulmonary complications' named entity 'risk factor' named entity 'respiratory complications' named entity 'clinical trials' named entity 'NHL' named entity 'rituximab' named entity 'respiratory complications' named entity 'R-CHOP' named entity 'CHF' named entity 'lung toxicity' named entity 'clinical trials' named entity 'respiratory complications' named entity 'FDG-PET' named entity 'follow-up' named entity 'adverse reactions' named entity 'Respiratory complications' named entity 'respiratory complications' named entity 'acute respiratory failure'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software